Cynata Therapeutics completes patient enrolment in phase 2 trial of CYP-001 in adults with newly diagnosed, high risk aGvHD: Melbourne, Australia Tuesday, December 16, 2025, 14:00 ...

Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic neuron ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

“To provide menstruating patients with sickle cell disease the best care, primary care physicians, gynecologists, and ...

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

Châtillon, France, December 16, 2025DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of ...

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces the completion of cohort 2a in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001.

The existing clinical data supporting safety and efficacy of CardiAMP Cell Therapy for HFrEF is subject to ongoing regulatory discussions in Japan and the United States. The compilation includes data ...

Presence of increased fat tissue (epicardial fat) around the heart significantly contributes to greater damage of heart ...

By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.